The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Ansichten
• 07/18/23
0
0
Einbetten
administrator
Abonnenten
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
Zeig mehr
Facebook Kommentare
SORT BY-
Beste Kommentare
-
Neueste Kommentare